Ascentage Pharma Group International
AAPG24.520USD
+0.330+1.36%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
0.00시가총액
--P/E TTM
자세한 내용은 Ascentage Pharma Group International 회사
Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.
Ascentage Pharma Group International 정보
종목 코드 AAPG
회사 이름Ascentage Pharma Group International
상장일Oct 28, 2019
CEOYang (Dajun)
직원 수- -
유형Depository Receipt
회계 연도 종료- -
주소68 Xinqing Road, Suzhou Industrial Park
도시SUZHOU
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가China
우편 번호- -
전화
웹사이트https://www.ascentage.cn/
종목 코드 AAPG
상장일Oct 28, 2019
CEOYang (Dajun)
Ascentage Pharma Group International의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Dajun Yang, M.D., Ph.D.
Dr. Dajun Yang, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Shaomeng Wang, Ph.D.
Dr. Shaomeng Wang, Ph.D.
Non-Executive Director, Co-Founder
Non-Executive Director, Co-Founder
--
--
Dr. Dazhong (Simon) Lu, Ph.D.
Dr. Dazhong (Simon) Lu, Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Wei Ren
Mr. Wei Ren
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. Yifan Zhai, M.D., Ph.D.
Dr. Yifan Zhai, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Raymond Jeffrey (Jeff) Kmetz
Mr. Raymond Jeffrey (Jeff) Kmetz
Chief Business Officer
Chief Business Officer
--
--
Mr. Thomas Joseph (Tom) Knapp, J.D.
Mr. Thomas Joseph (Tom) Knapp, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Ms. Marina S. Bozilenko
Ms. Marina S. Bozilenko
Independent Non-Executive Director
Independent Non-Executive Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Dajun Yang, M.D., Ph.D.
Dr. Dajun Yang, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Shaomeng Wang, Ph.D.
Dr. Shaomeng Wang, Ph.D.
Non-Executive Director, Co-Founder
Non-Executive Director, Co-Founder
--
--
Dr. Dazhong (Simon) Lu, Ph.D.
Dr. Dazhong (Simon) Lu, Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Wei Ren
Mr. Wei Ren
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Tue, Jan 20
마지막 업데이트: Tue, Jan 20
주주
주주 유형
주주
주주
비율
XY Capital Ltd.
0.02%
Point72 (DIFC) Ltd
0.02%
NEOS Investment Management, LLC
0.01%
Citadel Advisors LLC
0.01%
기타
99.94%
주주
주주
비율
XY Capital Ltd.
0.02%
Point72 (DIFC) Ltd
0.02%
NEOS Investment Management, LLC
0.01%
Citadel Advisors LLC
0.01%
기타
99.94%
주주 유형
주주
비율
Investment Advisor
0.06%
Hedge Fund
0.01%
기타
99.93%
기관 주식 보유
마지막 업데이트: Mon, Dec 8
마지막 업데이트: Mon, Dec 8
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
23
89.21K
0.29%
--
2025Q3
23
89.21K
0.29%
+6.09K
2025Q2
16
82.77K
0.27%
-154.43K
2025Q1
6
237.19K
0.00%
+237.19K
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
XY Capital Ltd.
18.12K
0.02%
+12.53K
+224.15%
Sep 30, 2025
Point72 (DIFC) Ltd
17.93K
0.02%
-2.96K
-14.17%
Sep 30, 2025
NEOS Investment Management, LLC
10.38K
0.01%
-5.11K
-32.98%
Sep 30, 2025
Citadel Advisors LLC
9.65K
0.01%
+9.65K
--
Sep 30, 2025
UBS Financial Services, Inc.
18.34K
0.02%
+10.99K
+149.35%
Sep 30, 2025
Mirae Asset Global Investments (USA) LLC
2.46K
0%
+2.46K
--
Sep 30, 2025
Tower Research Capital LLC
829.00
0%
+829.00
--
Sep 30, 2025
Geode Capital Management, L.L.C.
361.00
0%
--
--
Nov 30, 2025
Osaic Holdings, Inc.
220.00
0%
+220.00
--
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
Tema Oncology ETF
0.43%
Invesco Golden Dragon China ETF
0%
Tema Oncology ETF
비율0.43%
Invesco Golden Dragon China ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
